SCIO-469

CAS No. 309913-83-5

SCIO-469( Talmapimod | SCIO469 | SCIO 469 )

Catalog No. M13991 CAS No. 309913-83-5

A potent, selective p38α MAPK inhibitor with IC50 of 9 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 63 Get Quote
5MG 105 Get Quote
10MG 168 Get Quote
25MG 357 Get Quote
50MG 530 Get Quote
100MG 759 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SCIO-469
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective p38α MAPK inhibitor with IC50 of 9 nM.
  • Description
    A potent, selective p38α MAPK inhibitor with IC50 of 9 nM; displays 10-fold selectivity for p38α over p38β, >2,000-fold selectivity over a panel of 20 other kinases, including other MAP kinases; decreases apoptosis in MDS CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation; enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells, and inhibits tumor growth in vivo.Rheumatoid Arthritis Phase 2 Discontinued.
  • In Vitro
    Talmapimod (SCIO-469) (100-200 nM; 1 hour) inhibits phosphorylation of p38 MAPK in MM cells.Talmapimod inhibits LPS-induced TNF-a production in human whole blood.Talmapimod decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells.Western Blot Analysis Cell Line:MM.1S, U266, RPMI8226, MM.1R, and RPMI-Dox40 cell lines Concentration:100, 200 nM Incubation Time:1 hour Result:Strongly inhibits phosphorylation of p38 MAPK.
  • In Vivo
    Targeting p38α MAPK with Talmapimod (SCIO-469) decreases myeloma burden in addition to preventing the development of myeloma bone disease.Talmapimod inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models.Talmapimod (10-90 mg/kg; p.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination. Animal Model:Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors)Dosage:P.o.; twice daily orally for 14 days Administration:10, 30, 90 mg/kg Result:Dose-dependently reduced tumor growth.
  • Synonyms
    Talmapimod | SCIO469 | SCIO 469
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    Inflammation/Immunology
  • Indication
    Rheumatoid Arthritis

Chemical Information

  • CAS Number
    309913-83-5
  • Formula Weight
    513.0035
  • Molecular Formula
    C27H30ClFN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CC1CN(C(CN1C(=O)C2=C(C=C3C(=C2)C(=CN3C)C(=O)C(=O)N(C)C)Cl)C)CC4=CC=C(C=C4)F
  • Chemical Name
    1H-Indole-3-acetamide, 6-chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-α-oxo-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Navas TA, et al. Leukemia. 2006 Jun;20(6):1017-27. 2. Navas TA, et al. Blood. 2006 Dec 15;108(13):4170-7. 3. Hideshima T, et al. Oncogene. 2004 Nov 18;23(54):8766-76.
molnova catalog
related products
  • TAK1-IN-3

    TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.

  • Rosin

    Rosin is a natural productmay have therapeutic potential for the treatment of inflammation.

  • TAK-715

    A potent, selective, orally active p38α MAPK inhibitor with IC50 of 7.1 nM.